ESR1 and breast carcinoma: Given that tumor grade (III), MP2 class, ER-low, and PD-L1+ status have been used or proposed for patient selection and efficacy evaluation in recent IO trials in early-stage HR+HER2– breast cancer,2,3 we compared their performance with ImPrint.